2025
Intrathecal Dexamethasone as a FIRES Extinguisher: A 12-Patient Clinical Experience with Usage of Intrathecal Dexamethasone for Febrile Infection-Related Epilepsy Syndrome
Farias-Moeller R, Hanin A, Ahsan S, Brooks J, Caganap S, Czeisler B, Cheuret E, Cocuzzo B, Hahn C, Kyureghyan H, Marcoux M, Mohamed R, Park C, Stern Zimmer M, Barun V, Lai Y, Hirsch L. Intrathecal Dexamethasone as a FIRES Extinguisher: A 12-Patient Clinical Experience with Usage of Intrathecal Dexamethasone for Febrile Infection-Related Epilepsy Syndrome. Neurocritical Care 2025, 1-9. PMID: 40279013, DOI: 10.1007/s12028-025-02254-9.Peer-Reviewed Original ResearchFebrile infection-related epilepsy syndromeIT-DEXLong-term outcomesIntrathecal dexamethasoneDosing strategiesEpilepsy syndromesElevated levels of proinflammatory markersLevels of proinflammatory markersRefractory status epilepticusRefractory status epilepticus onsetStatus epilepticus onsetInternational multicenter cohortPersistently elevated levelsEvaluates treatment timeNo adverse effectsMedian doseResultsAll patientsCytokine profileMulticenter cohortCytokine analysisStatus epilepticusClinical outcomesContinuous infusionProinflammatory markersRetrospective analysis
2024
1583-P: Measuring Mitochondrial Metabolism In Vivo with [1,2-13C2]-L-Glutamine Mass Isotopomers
SIEBEL S, CARDONE R, MASON G, KIBBEY R. 1583-P: Measuring Mitochondrial Metabolism In Vivo with [1,2-13C2]-L-Glutamine Mass Isotopomers. Diabetes 2024, 73 DOI: 10.2337/db24-1583-p.Peer-Reviewed Original Research
2023
Status epilepticus in the ICU
Rossetti A, Claassen J, Gaspard N. Status epilepticus in the ICU. Intensive Care Medicine 2023, 50: 1-16. PMID: 38117319, DOI: 10.1007/s00134-023-07263-w.Peer-Reviewed Original ResearchSuper-refractory status epilepticusIntensive care unitStatus epilepticusAntiseizure medicationsUnderlying causeContinuous video electroencephalographyAcute brain injuryConvulsive status epilepticusNon-pharmacologic approachesNonconvulsive status epilepticusShort-term mortalityCommon medical emergencyAutoimmune encephalitisMedical comorbiditiesInitial managementSignificant morbidityCare unitCardiac arrestResponsive casesVideo electroencephalographyContinuous infusionBrain injuryRapid administrationSevere casesMedical emergencyBradykinin B2 receptor blockade and intradialytic hypotension
Gamboa J, Mambungu C, Clagett A, Nian H, Yu C, Ikizler T, Brown N. Bradykinin B2 receptor blockade and intradialytic hypotension. BMC Nephrology 2023, 24: 134. PMID: 37170244, PMCID: PMC10176680, DOI: 10.1186/s12882-023-03192-4.Peer-Reviewed Original ResearchConceptsBradykinin B2 receptor blockadeB2 receptor blockadeMaintenance hemodialysisBlood pressureReceptor blockersReceptor blockadeIntradialytic hypotensionBradykinin B2 receptor blockerLack of vasoconstrictionProduction of vasodilatorsSystolic blood pressureGroup of patientsCrossover clinical trialCommon clinical complicationHemodynamic effectsClinical complicationsContinuous infusionClinical trialsStratified analysisIcatibantHemodialysisPatientsHypotensionPlaceboCompensatory mechanisms
2022
A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies
Boddu P, Senapati J, Ravandi‐Kashani F, Jabbour E, Jain N, Ayres M, Chen Y, Keating M, Kantarjian H, Gandhi V, Kadia T. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 2022, 129: 580-589. PMID: 36448227, PMCID: PMC12002038, DOI: 10.1002/cncr.34570.Peer-Reviewed Original ResearchConceptsPhase 1 studyT-cell prolymphocytic leukemiaComplete remissionContinuous infusionRefractory T-cell acute lymphoblastic leukemiaCentral nervous system toxicityIncomplete platelet recoveryRefractory lymphoid malignanciesT-cell acute lymphoblastic leukemiaUse of nelarabineFavorable clinical responseNervous system toxicityOverall response rateContinuous infusion scheduleAcute lymphoblastic leukemiaClinical responseCentral neurotoxicityLymphoblastic lymphomaMedian agePeripheral neuropathyInfusion scheduleSafety profilePatient populationLymphoblastic leukemiaPlatelet recovery
2020
Association of Heparin Dose, Route, Timing, and Duration With Heparin-Induced Thrombocytopenia
Crow JR, Nam L, Chasler JE, Ong CS, Dane KE, Kickler T, Lawton J, Streiff MB, Alejo D, Canner JK, Schena S. Association of Heparin Dose, Route, Timing, and Duration With Heparin-Induced Thrombocytopenia. The Annals Of Thoracic Surgery 2020, 112: 32-37. PMID: 33217393, DOI: 10.1016/j.athoracsur.2020.09.033.Peer-Reviewed Original ResearchConceptsCardiac surgery patientsAdult cardiac surgery patientsSurgery patientsUFH doseHeparin doseRetrospective case-control studyMultivariable conditional logistic regressionCardiopulmonary bypass durationHIT-positive patientsPrevalence of heparinUnfractionated heparin doseHeparin-Induced ThrombocytopeniaReceiver-operating characteristic curveCase-control studyConditional logistic regressionBypass durationIntravenous UFHUFH administrationUFH infusionSubcutaneous routeContinuous infusionMean agePatientsTotal doseLogistic regression
2017
Baclofen Pumps
Woolf SM, Baum CR. Baclofen Pumps. Pediatric Emergency Care 2017, 33: 271-275. PMID: 28353527, DOI: 10.1097/pec.0000000000001090.Peer-Reviewed Original ResearchConceptsIntrathecal baclofen therapyBaclofen therapySpinal cord conditionsMechanism of actionBaclofen pumpSignificant morbidityContinuous infusionBolus dosingPediatric cliniciansPediatric settingAbdominal wallImplanted pumpComplicationsTherapyMorbiditySpasticityBaclofenDystoniaInfusionDosingCliniciansBrain
2016
Treatment of Edema Associated With Intracerebral Hemorrhage
Leasure A, Kimberly WT, Sansing LH, Kahle KT, Kronenberg G, Kunte H, Simard JM, Sheth KN. Treatment of Edema Associated With Intracerebral Hemorrhage. Current Treatment Options In Neurology 2016, 18: 9. PMID: 26874842, DOI: 10.1007/s11940-015-0392-z.Peer-Reviewed Original ResearchPerihematomal edemaIntracerebral hemorrhageHypertonic salineFirst-line medical therapyTreatment of ICHWorse clinical outcomesLarge clinical trialsSubsequent continuous infusionTreatment of edemaEdema refractoryClinical deteriorationBrain herniationCommon complicationDecompressive craniectomyMedical therapyClinical outcomesContinuous infusionEdema formationClinical trialsBolus formClinical researchHemorrhageNext major advanceEdemaPilot study
2015
Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design
Sheth KN, Elm JJ, Beslow LA, Sze GK, Kimberly WT. Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design. Neurocritical Care 2015, 24: 132-139. PMID: 26268138, DOI: 10.1007/s12028-015-0189-7.Peer-Reviewed Original ResearchConceptsAdverse eventsCerebral edemaContinuous infusionHigh riskAnterior circulation ischemic strokeDiffusion-weighted image (DWI) lesionsAnterior circulation infarctionLarge territory infarctionMalignant cerebral edemaPrimary efficacy outcomeSerious adverse eventsLarge hemispheric strokeYears of ageStudy infusionEfficacy outcomesTerritory infarctionIschemic strokeNeurological deteriorationRankin ScaleSymptom onsetDecompressive craniectomyMulticenter trialBrain edemaHemispheric strokeStroke trialsDose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]
Paidas M, Frieling J, de Jongh J, Drenth H, Streisand J. Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]. Obstetrics And Gynecology 2015, 125: 52s. DOI: 10.1097/01.aog.0000463689.71574.8f.Peer-Reviewed Original ResearchEarly-onset preeclampsiaRecombinant human antithrombinPhase 3 trialPopulation pharmacokinetic modelingHuman antithrombinAntithrombin deficiencyPlasma antithrombinPharmacokinetic modelingHereditary antithrombin deficiencyPopulation pharmacokinetic modelAntithrombin activity levelsDifferent pharmacokinetic propertiesPrior human studiesExpectant managementPerinatal morbidityPregnant patientsLoading doseMaternal administrationPregnant womenContinuous infusionSimilar efficacyClinical studiesPleiotropic effectsAntithrombin treatmentDose selection
2014
Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers: A Systematic Review and Meta-analysis
Sachar H, Vaidya K, Laine L. Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers: A Systematic Review and Meta-analysis. JAMA Internal Medicine 2014, 174: 1755-1762. PMID: 25201154, PMCID: PMC4415726, DOI: 10.1001/jamainternmed.2014.4056.Peer-Reviewed Original ResearchConceptsHigh-risk bleeding ulcersProton pump inhibitorsAbsolute risk differencePPI therapyBleeding ulcersContinuous infusionRisk differenceRisk ratioSystematic reviewDuplicate independent data extractionUrgent interventionRed blood cell transfusionGuideline-recommended regimenReduction of ulcerBlood cell transfusionCochrane Central RegisterControlled Trials databasesTrial of patientsData extractionIndependent data extractionIntravenous bolus doseRandom-effects modelFixed-effects modelPPI dosePPI infusionHuman NgR-Fc Decoy Protein via Lumbar Intrathecal Bolus Administration Enhances Recovery from Rat Spinal Cord Contusion
Wang X, Yigitkanli K, Kim CY, Sekine-Konno T, Wirak D, Frieden E, Bhargava A, Maynard G, Cafferty WB, Strittmatter SM. Human NgR-Fc Decoy Protein via Lumbar Intrathecal Bolus Administration Enhances Recovery from Rat Spinal Cord Contusion. Journal Of Neurotrauma 2014, 31: 1955-1966. PMID: 24964223, PMCID: PMC4245872, DOI: 10.1089/neu.2014.3355.Peer-Reviewed Original ResearchConceptsSpinal cord injuryTraumatic spinal cord injurySpinal cord contusionNeurological recoveryCord contusionRat spinal cord contusionSpinal contusion injuryLumbar intrathecal spaceLumbar spinal cordContinuous intracerebroventricular infusionRodent SCI modelsPercentage of ratsRaphespinal axonsContusion injuryAdministration regimenSCI modelContinuous infusionCord injuryIntracerebroventricular infusionIntrathecal spaceSpinal cordPreclinical modelsEffective treatmentWalking tasksClinical testingTransient Receptor Potential Melastatin 8 Channel Inhibition Potentiates the Hypothermic Response to Transient Receptor Potential Vanilloid 1 Activation in the Conscious Mouse
Feketa V, Zhang Y, Cao Z, Balasubramanian A, Flores C, Player M, Marrelli S. Transient Receptor Potential Melastatin 8 Channel Inhibition Potentiates the Hypothermic Response to Transient Receptor Potential Vanilloid 1 Activation in the Conscious Mouse. Critical Care Medicine 2014, 42: e355-e363. PMID: 24595220, PMCID: PMC4137592, DOI: 10.1097/ccm.0000000000000229.Peer-Reviewed Original ResearchConceptsTRP melastatin 8TRP vanilloid 1Transient receptor potential channelsConscious miceTRPM8 inhibitorTransient receptor potential vanilloid 1 (TRPV1) activationCore temperatureAged male miceProspective animal studyAcademic medical centerPotential channelsCerebral ischemiaLoading doseDose-dependent dropMechanical ventilationVanilloid 1TRPV1 agonistsCardiac arrestCold defense responsesContinuous infusionAged miceHypothermic effectTherapeutic rangeMale miceHypothermic response
2013
Use of Continuous Local Anesthetic Infusion in the Management of Postoperative Split-Thickness Skin Graft Donor Site Pain
Hernandez JL, Savetamal A, Crombie RE, Cholewczynski W, Atweh N, Possenti P, Schulz JT. Use of Continuous Local Anesthetic Infusion in the Management of Postoperative Split-Thickness Skin Graft Donor Site Pain. Journal Of Burn Care & Research 2013, 34: e257-e262. PMID: 23271060, DOI: 10.1097/bcr.0b013e3182721735.Peer-Reviewed Original ResearchConceptsContinuous local anesthetic infusionLocal anesthetic infusionSplit-thickness skin graftDonor site painAnesthetic infusionSite painDonor siteDual catheter systemCatheter insertion siteEarly postoperative periodPain severity scorePostoperative day 3Second postoperative dayMost donor sitesPain scoresPain controlPostoperative complicationsPatient characteristicsPostoperative dayPostoperative periodSignificant painSubcutaneous catheterContinuous infusionSeverity scoreInfusion duration
2012
Prevention of chemotherapy-induced damage to ovarian reserve by sphingosine-1-phosphate
LI F, Ozkaya E, Akula K, Desutter P, Oktay K. Prevention of chemotherapy-induced damage to ovarian reserve by sphingosine-1-phosphate. Journal Of Clinical Oncology 2012, 30: 1097-1097. DOI: 10.1200/jco.2012.30.15_suppl.1097.Peer-Reviewed Original ResearchFollicle deathOvarian functionApoptotic folliclesOvarian reserveChemotherapy agentsPrimordial folliclesMini-osmotic pumpsOld NOD miceChemotherapy-induced damageAssisted reproduction techniquesSphingosine-1-PhosphateChemotherapy injectionsNOD miceContinuous infusionTotal folliclesPharmacological meansD groupS1P treatmentMouse ovariesPathway inhibitorCytotoxic agentsFolliclesS1PDeathSignificant decrease
2011
Dipyridamole-Associated Shock and Pulmonary Edema
Dioverti M, Fishman R, Moskowitz R, Arias SA, Nair S, Lall P, Schussheim AE, Zarich S, Manthous C. Dipyridamole-Associated Shock and Pulmonary Edema. Annals Of Pharmacotherapy 2011, 45: 1027-1027. PMID: 21672887, DOI: 10.1345/aph.1p734.Peer-Reviewed Original ResearchConceptsNoncardiogenic pulmonary edemaDipyridamole myocardial scintigraphyPulmonary edemaSevere pulmonary edemaCardiopulmonary collapseMyocardial scintigraphyNew left ventricular dysfunctionPositive end-expiratory pressureObjective causality assessmentLeft ventricular dysfunctionEnd-expiratory pressureMechanism of shockFulminant shockInvasive ventilationMultiple vasopressorsCardiovascular collapseHypovolemic shockShock refractoryCase seriesDipyridamole infusionEchocardiography resultsEndotracheal intubationIntravenous dipyridamoleContinuous infusionIntravenous infusionDiuretic Strategies in Patients with Acute Decompensated Heart Failure
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart B, Mascette AM, Braunwald E, O'Connor CM. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal Of Medicine 2011, 364: 797-805. PMID: 21366472, PMCID: PMC3412356, DOI: 10.1056/nejmoa1005419.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedArea Under CurveCreatinineDiureticsDouble-Blind MethodDrug Administration ScheduleDyspneaFemaleFurosemideHeart FailureHumansInfusions, IntravenousInjections, IntravenousIntention to Treat AnalysisKaplan-Meier EstimateMaleMiddle AgedSodium Potassium Chloride Symporter InhibitorsConceptsAcute decompensated heart failureDecompensated heart failurePatient global assessmentHeart failureCreatinine levelsContinuous infusionHigh-dose strategyGlobal assessmentRenal functionMean changeLow doseHigh doseSignificant differencesCoprimary end pointsSerum creatinine levelsHigh-dose groupLow-dose strategyVisual analog scaleComparison of BolusDiuretic strategyDiuretic therapyTransient worseningGreater diuresisDose adjustmentLoop diuretics
2010
Transient Brachial Plexus Palsy: An Unusual Complication of Paravertebral Infusion of Local Anesthetic
D'Souza D, Sondergaard K, Detterbeck FC. Transient Brachial Plexus Palsy: An Unusual Complication of Paravertebral Infusion of Local Anesthetic. The Annals Of Thoracic Surgery 2010, 90: e75-e76. PMID: 20971226, DOI: 10.1016/j.athoracsur.2010.07.071.Peer-Reviewed Original Research
2009
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, Liebes L, Muggia F. Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemotherapy And Pharmacology 2009, 64: 803. PMID: 19221754, PMCID: PMC3901370, DOI: 10.1007/s00280-009-0931-y.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsPhase INon-hematologic tumorsPhase II dosesPhase II doseDose-limiting toxicityResultsFifty-three patientsBlood mononuclear cellsNon-hematologic malignanciesBryostatin 1Cytotoxicity of cisplatinCisplatin 50PurposePreclinical dataObjective responseContinuous infusionMononuclear cellsTolerable dosesProtein kinase C modulatorsCisplatin effectComputerized tomographyPatientsConsistent inhibitionCisplatin cytotoxicityCisplatinMinimal toxicity
2008
Evaluating the process of care in nonvariceal upper gastrointestinal haemorrhage: a survey of expert vs. non‐expert gastroenterologists
ESRAILIAN E, GRALNEK IM, JENSEN D, LAINE L, DULAI GS, EISEN G, SPIEGEL BM. Evaluating the process of care in nonvariceal upper gastrointestinal haemorrhage: a survey of expert vs. non‐expert gastroenterologists. Alimentary Pharmacology & Therapeutics 2008, 28: 1199-1208. PMID: 18729846, DOI: 10.1111/j.1365-2036.2008.03838.x.Peer-Reviewed Original ResearchConceptsHigh-risk bleedingProcess of careIntravenous proton pump inhibitorsNonvariceal upper gastrointestinal hemorrhageUpper gastrointestinal tract hemorrhageLarge-channel endoscopeUpper gastrointestinal hemorrhageUse of hemoclipsGastrointestinal tract hemorrhageProton pump inhibitorsChoice of endoscopeNasogastric lavageGastrointestinal hemorrhageTract hemorrhagePromotility agentsContinuous infusionPump inhibitorsGuideline complianceWide variationBleedingHemorrhageGastroenterologistsVignette surveyCareEndoscope
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply